🔗 Share this article

As the United States continues making sweeping adjustments to its vaccine recommendations, one figure appears unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about Covid shots throughout the pandemic and has focused upon alleged deaths following COVID-19 vaccination in her recent time at the FDA.

Planned Shifts to Childhood Vaccine Schedule

Public health authorities were set to unveil sweeping revisions to the pediatric immunization program recently, synchronizing the US with the Danish national calendar, it is understood – a major change that would put the US out of step with many the world with insufficient data for public health gain. This reveal has been pushed back until the new year.

Rather than the director of the vaccine center, Dr. Høeg is set to present at the gathering. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth appointee to head the office this calendar year.

A New Direction at the Agency

This interim role may indicate a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Dr. Prasad solidify control at the FDA – and it points to a renewed priority upon dismantling already-approved vaccines at the FDA.

The new acting director has often pushed for discontinuing specific pediatric shot schedules in the US to become more in line with Denmark, a country with nationalized medicine and a population about the population of the state of Wisconsin.

In her initial statements, she has continued to focus on vaccination policy – usually the purview of Dr. Prasad, head of the FDA’s CBER – as opposed to medication approval.

Doubts Over Qualifications

Høeg has little discernible background in drug development, approval processes or management, which has been customary for previous heads of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since spring.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in leading a large organization. She lacks background in drug approvals.”

Previous directors of the center would “be deeply familiar with regulatory frameworks and the research of drug development”, commented a former acting FDA commissioner. “Objectively, she lacks the type of experience that former directors who headed the center have had.”

This division has an immense workload at the FDA, Woodcock stated.

“The public just pays attention on the new drug program, but the generic drug division approves a multitude of generic drugs. There’s a biosimilars program, non-prescription drug unit and more, and each of these need to be managed,” Woodcock said. “The responsibility you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a substantial management aspect to the job, which oversees over 5,000 personnel. “It is a huge leadership role, if you perform it correctly,” the former official concluded.

Official Statement and Controversial Programs

Regarding questions about Dr. Høeg's credentials and whether this assignment signifies greater collaboration among agency officials on vaccines, a press secretary stated that the “questions rely on flawed premises”.

“Her experience aligns with the responsibilities of her position,” the spokesperson said, pointing to the months Høeg spent counseling the agency head on “drug safety and approval science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a disputed rapid drug-approval program that apparently troubled her former heads. “By what process are these drugs being picked for this fast-track system? Who is making the decisions?” Howard questioned. “There’s a lot of confidentiality occurring at the agency right now.”

In general, he said, “the FDA seems to be moving towards laxer oversight of pharmaceuticals, with the exception of immunizations.”

Established Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if problematic, track record, critics said. She released a research paper using unconfirmed volunteer-provided data to assess the rate of heart inflammation following COVID-19 vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to indicate Covid vaccines are pose a greater threat than they are.

Included in her “desired changes” for the new administration featured altering guidelines for recently developed shots and discontinuing “non-essential” immunizations, she said post-election on a podcast. At the FDA, Dr. Høeg has according to sources proposed barring teenage boys from receiving Covid vaccinations.

“She is an all-around ideologue who starts off with her beliefs and reverse-engineers to accommodate the evidence in a extremely deceptive, untruthful way,” Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg joined other contrarians, {like|